St Vincent's University Hospital

Greenwich LifeSciences Expands FLAMINGO-01 Breast Cancer Trial to Ireland, Adding to Global Network of 150 Sites

- Greenwich LifeSciences received European regulatory approval to expand its Phase III FLAMINGO-01 clinical trial to Ireland, adding to a global network of 150 trial sites across seven countries. - The trial evaluates GLSI-100 immunotherapy in HER2-positive breast cancer patients with residual disease or high-risk pathologic complete response after surgery and trastuzumab treatment. - Ireland diagnosed 3,723 new breast cancer cases in 2022, representing 30% of all cancers in women and the second leading cause of cancer death with 883 deaths. - Dr. Janice Walshe from St Vincent's University Hospital in Dublin will serve as national principal investigator, bringing extensive experience in international breast cancer trials.